D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target

Benzinga · 1d ago
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.